Generation Bio Co. (GBIO)

Market Cap	28.67M
Revenue (ttm)	19.89M
Net Income (ttm)	-131.67M
Shares Out	67.01M
EPS (ttm)	-1.98
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	530,860
Open	0.4500
Previous Close	0.4569
Day's Range	0.4122 - 0.4518
52-Week Range	0.4122 - 4.6500
Beta	2.72
Analysts	Strong Buy
Price Target	7.33 (+1,613.42%)
Earnings Date	Mar 13, 2025

About GBIO

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle, or ctLNP platform. ctLNP delivery system is designed to address the limitations of existing technologies and comprises three elements. First, LNP from interacting with serum-binding proteins and reduces clearance by the liver and spleen. Second, identify and refine a small format targeting ligand against a receptor uniquely expressed on the target cell to achieve highly potent and selec...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 12, 2020
• Employees: 115
• Stock Exchange: NASDAQ
• Ticker Symbol: GBIO
• Website: https://generationbio.com

Financial Performance

In 2024, Generation Bio Co.'s revenue was $19.89 million, an increase of 236.92% compared to the previous year's $5.90 million. Losses were -$131.67 million, 3.99% more than in 2023.

Analyst Forecast

According to 4 analysts, the average rating for GBIO stock is "Strong Buy." The 12-month stock price forecast is $7.33, which is an increase of 1,613.42% from the latest price.

Price Target

$7.33

(1,613.42% upside)

Analyst Consensus: Strong Buy